2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Safety of Iron Chelation in Patients with Brain Iron Overload

C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

Quality of Life  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease

A. Tozzi, M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Safinamide: real world evidence in Toledo´s Movement Disorders Unit

N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3